MapLight Therapeutics Inc(MPLT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.12 | Insider Own | 78.03% | Shs Outstand | 45.4M | Perf Week | -4.89% |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | 21.01% | Insider Trans | 12.28% | Shs Float | 12.2M | Perf Month | -21.29% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -1.2 | Inst Own | 26.88% | Short Float | 27.21% | Perf Quarter | -39.6% |
| Income | -0.23B | P/S | - | EPS this Y | 73.35% | Inst Trans | -1.39% | Short Ratio | 5.92 | Perf Half Y | -75.31% |
| Sales | 0.00B | P/B | 0.99 | EPS next 5Y | 40.14% | ROA | -101.59% | Short Interest | 3.32M | Perf YTD | -56.85% |
| Book/sh | 7.67 | P/C | 1.38 | EPS past 3/5Y | -71.59% - | ROE | -111.55% | 52W High | -81.25% ($40.43) | Perf Year | -58.74% |
| Cash/sh | 5.48 | P/FCF | - | Sales past 3/5Y | - | ROIC | -65.84% | 52W Low | 1.61% ($7.46) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.31% 7.19% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.52 | EPS Q/Q | -83.91% | Profit Margin | - | RSI (14) | 31.48 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.52 | Sales Q/Q | - | SMA20 | -8.7% ($8.3) | Beta | 2.8 | Target Price | $25.75 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -27.49% ($10.45) | Rel Volume | 0.7 | Prev Close | $7.72 |
| Employees | 133 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 2.16% - | SMA200 | -63.05% ($20.51) | Avg Volume(3M) | 0.56M | Price | $7.58 |
| IPO | 2025/10/27 | Option/Short | Yes/Yes | Trades | 4515 | Volume | 394,997 | Change | -1.81% |
🧠 MapLight Therapeutics (MPLT) is a clinical-stage biopharmaceutical company that targets central nervous system (CNS) disorders. It is a neuroscience-focused biotech developing muscarinic receptor-based novel drug candidates in high-unmet-need neuropsychiatric areas such as schizophrenia, autism spectrum disorder, and Alzheimer's disease psychosis, and is running multiple Phase 2 clinical programs simultaneously.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
MPLT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
27.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #230 of 597 in the industry
Based on market cap of $421M.
MPLT#230 MapLight Therapeutics Inc $421M PER - 
YDES#231 YD Bio Ltd $421M PER - 
CCCC#232 C4 Therapeutics Inc $415M PER - 
EDIT#233 Editas Medicine Inc $410M PER - 
ASMB#234 Assembly Biosciences Inc $410M PER - 
FAQ
What kind of company is MPLT?
MPLT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MPLT?
The market cap of MPLT is approximately $421M, ranking 3,289 within its sector.
What is the 52-week high and low for MPLT?
MPLT has recorded a 52-week high of $40.43 and a low of $7.46.
